Sanofi’s tolebrutinib fails primary endpoint in multiple sclerosis trial

Sanofi’s tolebrutinib fails primary endpoint in multiple sclerosis trial
Crypto

Listen to this article

0%

Bitcoin price today: ticks down below $90k amid risk-off mood; key US data awaitedInvesting.com -- Sanofi SA (EPA:SASY) said on Monday that its experimental drug tolebrutinib failed to meet its prima… [+141 chars]

Leave A Comment

Comments are moderated and may take time to appear.

Comments

No comments yet. Be the first to comment!

Stay Connected